Custom Designed Peptides Transport Hydrophobic Drug Compounds
By LabMedica International staff writers Posted on 20 Jun 2016 |
Image: Molecular model of a hydrogel consisting of custom peptide fibers with spaces - \"missing teeth\" - that can trap and deliver hydrophobic small-molecule drugs (Photo courtesy of I-Che Li, Rice University).
A bioengineering team has designed a novel class of drug-delivery peptides that coalesce into a hydrogel capable of transporting hydrophobic compounds within the hydrophobic cores of the peptide nanofibers.
Multidomain peptides (MDPs) provide biocompatible hydrogel scaffolds that are injectable and space-conforming, allowing for in situ delivery of a variety of drugs. Investigators at Rice University (Houston, TX, USA) demonstrated that through manipulation of the peptide primary sequence, a molecular cavity (missing tooth) could be incorporated into the hydrophobic core of these peptide nanofibers allowing for encapsulation and delivery of small molecule drugs with poor water solubility.
The investigators reported in the June 2, 2016, online edition of the journal Biomacromolecules that the drugs SN-38, daunorubicin, diflunisal, etodolac, levofloxacin, and norfloxacin could be encapsulated and released from multidomain peptide fibers. Steady-state fluorescence and drug release studies showed that hydrogels loaded with SN-38, diflunisal, and etodolac exhibited prolonged drug release profiles due to intrafibrillar drug encapsulation.
"Here, we have done something different - we modify the inside of the fibers," said senior author Dr. Jeffery Hartgerink, professor of chemistry and bioengineering at Rice University. "We remove part of the internal portion of the fiber – that is the missing tooth - and that is a hydrophobic environment. Hydrophilic molecules frequently do not need a delivery mechanism because you can inject them. They are water-soluble, they go into the blood and they are fine. But hydrophobic drugs are challenging to deliver. We load them into the interstices of these fibers, and they can be delivered wherever we inject the hydrogel."
Related Links:
Rice University
Multidomain peptides (MDPs) provide biocompatible hydrogel scaffolds that are injectable and space-conforming, allowing for in situ delivery of a variety of drugs. Investigators at Rice University (Houston, TX, USA) demonstrated that through manipulation of the peptide primary sequence, a molecular cavity (missing tooth) could be incorporated into the hydrophobic core of these peptide nanofibers allowing for encapsulation and delivery of small molecule drugs with poor water solubility.
The investigators reported in the June 2, 2016, online edition of the journal Biomacromolecules that the drugs SN-38, daunorubicin, diflunisal, etodolac, levofloxacin, and norfloxacin could be encapsulated and released from multidomain peptide fibers. Steady-state fluorescence and drug release studies showed that hydrogels loaded with SN-38, diflunisal, and etodolac exhibited prolonged drug release profiles due to intrafibrillar drug encapsulation.
"Here, we have done something different - we modify the inside of the fibers," said senior author Dr. Jeffery Hartgerink, professor of chemistry and bioengineering at Rice University. "We remove part of the internal portion of the fiber – that is the missing tooth - and that is a hydrophobic environment. Hydrophilic molecules frequently do not need a delivery mechanism because you can inject them. They are water-soluble, they go into the blood and they are fine. But hydrophobic drugs are challenging to deliver. We load them into the interstices of these fibers, and they can be delivered wherever we inject the hydrogel."
Related Links:
Rice University
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples